{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:41:16Z","timestamp":1792269676638,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"DOI":"10.7759\/cureus.115307","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:41:52Z","timestamp":1787852512000},"source":"Crossref","is-referenced-by-count":1,"title":["Tofacitinib-Associated Acne in a Young Patient With Severe Atopic Dermatitis"],"prefix":"10.7759","author":[{"given":"Sabrina","family":"Oujdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouiame","family":"El Jouari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Gallouj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger S","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018, 4:1. 10.1038\/s41572-018-0001-z","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber T","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022, 21:21-40. 10.1038\/s41573-021-00266-6","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154431","article-title":"The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review","volume":"11","author":"Tsiogka A","year":"2022","unstructured":"Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, Nicolaidou E, Stratigos A, Rigopoulos D, Gregoriou S. The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review. J Clin Med. 2022, 11:10.3390\/jcm11154431","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy LL","year":"2015","unstructured":"Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015, 73:395-9. 10.1016\/j.jaad.2015.06.045","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: part I. a comprehensive review","volume":"86","author":"Chapman S","year":"2022","unstructured":"Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part I. a comprehensive review. J Am Acad Dermatol. 2022, 86:406-13. 10.1016\/j.jaad.2021.07.002","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez J","year":"2023","unstructured":"Martinez J, Manjaly C, Manjaly P, Ly S, Zhou G, Barbieri J, Mostaghimi A. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023, 159:1339-45. 10.1001\/jamadermatol.2023.3830","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01789-x","article-title":"Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis","volume":"72","author":"Sun C","year":"2023","unstructured":"Sun C, Su Z, Zeng YP. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis. Inflamm Res. 2023, 72:1861-71. 10.1007\/s00011-023-01789-x","journal-title":"Inflamm Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2397477","article-title":"Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis","volume":"35","author":"Chen BL","year":"2024","unstructured":"Chen BL, Huang S, Dong XW, Wu DD, Bai YP, Chen YY. Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis. J Dermatolog Treat. 2024, 35:2397477. 10.1080\/09546634.2024.2397477","journal-title":"J Dermatolog Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.012","article-title":"Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials","volume":"87","author":"Mendes-Bastos P","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al.. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022, 87:784-91. 10.1016\/j.jaad.2022.06.012","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.09.029","article-title":"A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis","volume":"30","author":"Lee SD","year":"2022","unstructured":"Lee SD, Ahn HJ, Shin MK. A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis. JAAD Case Rep. 2022, 30:11-6. 10.1016\/j.jdcr.2022.09.029","journal-title":"JAAD Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.25259\/CSDM_81_2023","article-title":"Tofacitinib-induced acne in a patient of vitiligo vulgaris: a case report","volume":"3","author":"Biswal A","year":"2023","unstructured":"Biswal A, Samal A, Panda M. Tofacitinib-induced acne in a patient of vitiligo vulgaris: a case report. CosmoDerma. 2023, 3:80. 10.25259\/CSDM_81_2023","journal-title":"CosmoDerma"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00961-9","article-title":"Acne among Japanese patients with atopic dermatitis receiving upadacitinib in the Phase 3 Rising Up study","volume":"13","author":"Hayashi N","year":"2023","unstructured":"Hayashi N, Ikeda M, Liu J, Raymundo E, Liu Y, Sasaki T, Yamasaki K. Acne among Japanese patients with atopic dermatitis receiving upadacitinib in the Phase 3 Rising Up study. Dermatol Ther (Heidelb). 2023, 13:1817-30. 10.1007\/s13555-023-00961-9","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14563","article-title":"Activation of Janus kinase signaling pathway in acne lesions","volume":"34","author":"Awad SM","year":"2021","unstructured":"Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther. 2021, 34:e14563. 10.1111\/dth.14563","journal-title":"Dermatol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.10.600","article-title":"Patients with granuloma annulare treated with Jak inhibitors show Cutibacterium acnes expansion: a clue to the mechanism underlying acneiform eruptions seen with Jak inhibitors","volume":"146","author":"Wang Y","year":"2026","unstructured":"Wang Y, Hernandez E, Junejo MH, Damsky W. Patients with granuloma annulare treated with Jak inhibitors show Cutibacterium acnes expansion: a clue to the mechanism underlying acneiform eruptions seen with Jak inhibitors. J Invest Dermatol. 2026, 146:1424-1427.e4. 10.1016\/j.jid.2025.10.600","journal-title":"J Invest Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0099-z","article-title":"Recent advances in acne pathogenesis: implications for therapy","volume":"15","author":"Das S","year":"2014","unstructured":"Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014, 15:479-88. 10.1007\/s40257-014-0099-z","journal-title":"Am J Clin Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17981","article-title":"Homeostasis of the sebaceous gland and mechanisms of acne pathogenesis","volume":"181","author":"Clayton RW","year":"2019","unstructured":"Clayton RW, G\u00f6bel K, Niessen CM, Paus R, van Steensel MA, Lim X. Homeostasis of the sebaceous gland and mechanisms of acne pathogenesis. Br J Dermatol. 2019, 181:677-90. 10.1111\/bjd.17981","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang IH","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022, 13:1068260. 10.3389\/fimmu.2022.1068260","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/528711-tofacitinib-associated-acne-in-a-young-patient-with-severe-atopic-dermatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:41:52Z","timestamp":1787852512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/528711-tofacitinib-associated-acne-in-a-young-patient-with-severe-atopic-dermatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.115307","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}